Overview

Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)

Status:
Not yet recruiting

Trial end date:
2024-06-04

Target enrollment:

Participant gender:

Summary

This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department setting.

Phase:

Phase 2

Details

Lead Sponsor:

Tonix Pharmaceuticals, Inc.

Collaborators:

National Institute on Drug Abuse (NIDA)
Premier

Treatments:

Cocaine